Multi-cancer early detection (MCED) assays represent a new paradigm in cancer screening with the potential to deliver on the promise of earlier detection of many cancers with a single test. This technology is quickly moving into the mainstream, which means more patients will be asking about it. In this webinar, we will explore the results of the Pathfinder Study, which evaluated the Galleri test, and we'll hear how practitioners are implementing this cutting-edge technology into their practices.
Innovation in Personalized Medicine and Population Health Speaker Series
Multi-Cancer Early Detection: Understanding the Pathfinder Study and Clinical Implementation
December 8, 2022
12 - 1 pm ET
Presenters:
Mylynda Massart, MD, PhD
Medical Director, UPMC Primary Care Precision Medicine Center
Assistant Professor, University of Pittsburgh
Eric Klein, MD
Emeritus Chairman, Glickman Urological & Kidney Institute
Professor of Surgery, Cleveland Clinic Lerner College of Medicine
Moderator:
Alexis Skoufalos, EdD
Associate Professor
Associate Dean, Strategic Development
Program Director, DHSc in Population Health